SPP1 and stroke disorder: Treatment with anti-osteopontin antibody 4 and 15 h after tMCAO in mice led to improved survival (Fig. 2b), significant improvement in neurological deficit scores, including motor function and reflexes scores (Fig. 2c), and significantly reduced hemorrhagic transformation of stroke lesions (Fig. 2d), edema (Fig. 2e) and infarct volumes (Fig. 2f).